Matthew B. Rettig

Matthew Rettig is a leading academic prostate cancer physician-scientist at UCLA's Jonsson Comprehensive Cancer Center and the VA Greater Los Angeles Healthcare System, where he serves as Chief of Hematology-Oncology. He has played an important role in establishing the treatment landscape for non-metastatic castration-resistant prostate cancer (nmCRPC), a disease state defined by rising PSA during androgen deprivation therapy with no detectable metastases on conventional imaging. Rettig was a key investigator in the PROSPER trial, which evaluated enzalutamide in men with high-risk nmCRPC (PSA doubling time ≤10 months) and demonstrated a significant improvement in metastasis-free survival (36.6 months vs. 14.7 months for placebo), leading to FDA approval for this indication in 2018. This approval helped establish nmCRPC as a treatable disease state distinct from metastatic CRPC and highlighted the importance of PSA kinetics in identifying patients at highest risk for rapid metastatic progression. His laboratory has also contributed to understanding resistance mechanisms in CRPC, including studying the role of the PI3K-AKT pathway, AR co-regulators, and epigenetic alterations in driving treatment resistance. Additionally, Rettig has been a champion of studying prostate cancer outcomes specifically in veterans, a population with unique clinical characteristics and disparate access to care. His work bridges high-impact clinical trials and mechanistic laboratory research, making him a distinctive figure in the GU oncology community.

Matthew Rettig 是 UCLA 强森综合癌症中心和大洛杉矶退伍军人医院的领先前列腺癌医学科学家。他在 PROSPER 试验中发挥了重要作用，该试验评估了恩扎鲁胺在高风险非转移性去势抵抗性前列腺癌（nmCRPC）中的疗效，证明了其将无转移生存期从14.7个月提升至36.6个月，从而在2018年获得FDA批准。 他的实验室还研究了 CRPC 的耐药机制，包括 PI3K-AKT 通路、AR 共调节因子和表观遗传学改变的作用。Rettig 还是研究退伍军人前列腺癌预后的倡导者，为弥合临床试验与机制研究做出了贡献。